SAN DIEGO, June 9, 2010 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the
Goldman Sachs 31st Annual Global Healthcare Conference in
Los Angeles on Wednesday, June 16, 2010 at 12:20 p.m. ET / 9:20 a.m.
PT. Daniel M.
Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will provide a corporate overview.
The presentation will be webcast live through the "Investors"
section of Amylin's corporate Web site at www.amylin.com, and a
recording will be made available on the Web site following the
event. To access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.